An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

March 31, 2018

Conditions
Primary Biliary Cirrhosis
Interventions
DRUG

LUM001

LUM001 administered orally once each day.

Trial Locations (18)

10021

Weill Cornell Medical College, New York

23249

Hunter Holmes McGuire VA Medical Center, Richmond

23602

Liver Institute of Virginia, Newport News

33136

University of Miami, Miami

40202

University of Louisville, Louisville

46202

Indiana University, Indianapolis

48202

Henry Ford Health System, Detroit

55114

Minnesota Gastroenterology, Saint Paul

63104

St. Louis University, St Louis

75390

University of Texas Southwestern Medical Center, Dallas

92037

Scripps Clinic, La Jolla

95817

University of California at Davis, Sacramento

98104

University of Washington Harborview Medical Center, Seattle

B15 2TT

University of Birmingham, Birmingham

L7 8XP

Royal Liverpool & Broadgreen University Hospital, Liverpool

NE1 4LP

Newcastle University, Newcastle upon Tyne

OX3 9DU

Oxford University Hospitals (John Radcliffe), Oxford

NW3 2QG

Royal Free Hospital, London

Sponsors
All Listed Sponsors
lead

Mirum Pharmaceuticals, Inc.

INDUSTRY